[HTML][HTML] Erlotinib after failure of gefitinib in patients with advanced non-small cell lung cancer previously responding to gefitinib
Background Gefitinib and erlotinib are two orally active epidermal growth factor receptor
tyrosine kinase inhibitors used in the treatment of advanced non-small cell lung cancer …
tyrosine kinase inhibitors used in the treatment of advanced non-small cell lung cancer …
Erlotinib in advanced non-small-cell lung cancer after gefitinib failure
ZT Zhou, XH Xu, Q Wei, M Lu, J Wang… - Cancer chemotherapy and …, 2009 - Springer
Purpose To evaluate the efficacy and safety of erlotinib in advanced non-small-cell lung
cancer after failure of gefitinib treatment. Patients and methods Patients with advanced or …
cancer after failure of gefitinib treatment. Patients and methods Patients with advanced or …
Phase II study of erlotinib in advanced non–small-cell lung cancer after failure of gefitinib
BC Cho, CK Im, MS Park, SK Kim, J Chang… - Journal of clinical …, 2007 - ascopubs.org
Purpose This study was designed to evaluate the efficacy and toxicity of erlotinib in patients
with advanced non–small-cell lung cancer (NSCLC) who experienced disease progression …
with advanced non–small-cell lung cancer (NSCLC) who experienced disease progression …
[HTML][HTML] Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer
AS Wong, R Soong, SBK Seah, SW Lim… - Journal of Thoracic …, 2008 - Elsevier
Introduction The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)
gefitinib and erlotinib are gaining an increasing role in the management of advanced non …
gefitinib and erlotinib are gaining an increasing role in the management of advanced non …
[HTML][HTML] Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment
DH Lee, SW Kim, C Suh, DH Yoon, EJ Yi, JS Lee - Annals of oncology, 2008 - Elsevier
Background: Both gefitinib and erlotinib are reversible epidermal growth factor receptor
tyrosine kinase inhibitors, but they have somewhat different pharmacological properties. We …
tyrosine kinase inhibitors, but they have somewhat different pharmacological properties. We …
[HTML][HTML] Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer
MK Wong, AI Lo, B Lam, WK Lam, MS Ip… - Cancer chemotherapy and …, 2010 - Springer
Purpose Chemotherapy is the mainstay treatment for advanced non-small cell lung cancer
(NSCLC). Gefitinib, an epidermal growth factor receptor—tyrosine kinase inhibitor (EGFR …
(NSCLC). Gefitinib, an epidermal growth factor receptor—tyrosine kinase inhibitor (EGFR …
Erlotinib as a salvage treatment for patients with advanced non-small cell lung cancer after failure of gefitinib treatment
Z Song, Y Yu, Z Chen, S Lu - Chinese Medical Journal, 2011 - mednexus.org
Background Several clinical trials showed that erlotinib was effective after the failure of
gefitinib in advanced non-small cell lung cancer (NSCLC). The aim of this study was to …
gefitinib in advanced non-small cell lung cancer (NSCLC). The aim of this study was to …
Lack of response to erlotinib after progression on gefitinib in patients with advanced non-small cell lung cancer
A Viswanathan, G Pillot, R Govindan - Lung Cancer, 2005 - lungcancerjournal.info
Epidermal growth factor receptor (EGFR) has been extensively studied as a target in the
treatment of non-small cell lung cancer. Gefitinib (ZD 1839, Iressa) and erlotinib (OSI 774 …
treatment of non-small cell lung cancer. Gefitinib (ZD 1839, Iressa) and erlotinib (OSI 774 …
[HTML][HTML] Erlotinib usage after prior treatment with gefitinib in advanced non-small cell lung cancer: A clinical perspective and review of published literature
Erlotinib and gefitinib are among the most widely researched, used and available
molecularly targeted therapies for treatment of advanced non-small cell lung cancer …
molecularly targeted therapies for treatment of advanced non-small cell lung cancer …
Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy
BACKGROUND: Gefitinib and erlotinib are commonly used for salvage therapy in patients
with nonsmall cell lung cancer (NSCLC) who have progressed on prior therapies. Although …
with nonsmall cell lung cancer (NSCLC) who have progressed on prior therapies. Although …
相关搜索
- lung cancer failure of gefitinib
- failure of gefitinib treatment
- lung cancer salvage treatment
- gefitinib in patients lack of response
- erlotinib in patients previous chemotherapy
- erlotinib in patients comparison of gefitinib
- asian patients gefitinib failure
- disease control gefitinib failure
- erlotinib in patients randomized phase
- lung cancer gefitinib treatment
- progression on gefitinib lack of response
- previous chemotherapy comparison of gefitinib